Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Jean‐Michel Molina(Délégation Paris 7), Jaime Andrade‐Villanueva(Hospital Civil de Guadalajara), Juan Echevarría(Hospital Nacional Cayetano Heredia), Ploenchan Chetchotisakd(Khon Kaen University), Jorge Alberto Corral, Neal David(Brooklyn Chest Hospital), Graeme Moyle(Chelsea and Westminster Hospital), Marco Mancini(Bristol-Myers Squibb (United States)), Lisa Percival(Bristol-Myers Squibb (United States)), Rong Yang(Bristol-Myers Squibb (United States)), Alexandra Thiry(Bristol-Myers Squibb (United States)), Donnie McGrath(Bristol-Myers Squibb (United States))
Cited by 482
Abstract
Related Papers
No related papers found
Powered by citation graph analysis